Back to Search Start Over

Efficacy and Safety of Eculizumab in Enteroaggregative E. coli Associated Hemolytic Uremic Syndrome.

Authors :
Acharya, Ratna
Clapp, William L.
Upadhyay, Kiran
Source :
Pediatric Reports. Mar2024, Vol. 16 Issue 1, p26-34. 9p.
Publication Year :
2024

Abstract

Background. Hemolytic uremic syndrome (HUS) may present atypically without the full triad of classical HUS. Eculizumab has been shown to be efficacious in complement-mediated atypical HUS and some cases of Shiga-toxin (ST) associated HUS. We report the utility of eculizumab in enteroaggregative E. coli (EAEC) associated HUS. Case summary. A female toddler presented with hemolytic anemia, oliguric acute kidney injury (AKI) without thrombocytopenia, and peripheral schistocytes. The stool examination for ST was negative but positive for EAEC. She required several hemodialysis sessions and received one dosage of eculizumab with rapid reversal of AKI and hemolytic markers. A kidney biopsy revealed acute tubular injury and segmental glomerular basement membrane splitting. Genetic testing was negative for complement mutations or deficiencies. A follow-up six months later showed persistently normal renal function and hematological markers. Conclusion. The clinical and histological manifestations of non-ST-associated diarrheal HUS and the role of eculizumab in this condition warrant future larger studies. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20367503
Volume :
16
Issue :
1
Database :
Academic Search Index
Journal :
Pediatric Reports
Publication Type :
Academic Journal
Accession number :
176364730
Full Text :
https://doi.org/10.3390/pediatric16010003